Arcus discontinues Phase 3 STAR-121 NSCLC trial; Gilead lets option rights lapse

Arcus Biosciences, Inc.

STAR-121 evaluating domvanalimab + zimberelimab + chemo vs pembro + chemo in 1L metastatic NSCLC stopped by IDMC for futility.
Zimberelimab + chemo showed comparable overall survival vs pembro + chemo; trial discontinued despite that.
Gilead declines option continuation payment; option period ends July 14, 2026; loses rights to CCR6, CD89, CD40L programs.
Gilead retains time-limited options for AB801 (AXL inhibitor), AB598 (anti-CD39), AB102 (MRGPRX2 antagonist), and TNF small molecule.
Arcus retains full rights to casdatifan program except Taiho territories (Japan and certain Asian countries).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.